WHO Updates: New Opioid Treatment & Overdose Guidelines

The World Health Organization (WHO) has announced updates to several recommendations regarding the treatment of opioid dependence and the community management of opioid overdose. These updates are part of forthcoming guidelines aimed at expanding access to effective care and reducing deaths associated with opioid use. The announcement underscores the critical need for affordable, ethical, and evidence-based support for individuals living with opioid dependence.

Opioid dependence remains a significant contributor to global morbidity and mortality. According to WHO estimates, opioids account for the largest share of the drug-related health burden, including fatal overdoses. The updated guidelines seek to address the gap between the number of people requiring treatment and those who currently receive it.

Global Burden of Opioid Use

Data from the World Health Organization highlights the scale of the challenge. In 2022, approximately 60 million people globally engaged in non-medical opioid use. This figure includes the use of substances such as heroin, morphine, codeine, fentanyl, methadone, tramadol, and other similar compounds.

More recent estimates from 2023 indicate that 316 million people worldwide used drugs, with around 61 million engaging in non-medical opioid use. Regular non-medical use, prolonged use, injection, misuse, and use without medical supervision can lead to opioid dependence and other serious health problems. These conditions are associated with a significant health burden across multiple regions.

The human cost of this crisis is reflected in mortality statistics. Of approximately 600,000 deaths attributed to drug use globally, about 450,000 are due to opioid use. These figures emphasize the urgency of implementing effective prevention, harm reduction, treatment, and care strategies.

Treatment Access Gaps

Despite the high prevalence of opioid dependence, access to treatment remains very limited. WHO estimates that some 64 million people globally live with drug use disorders. However, fewer than 10% of these individuals currently receive treatment.

Ensuring that people with opioid dependence and those at risk of opioid overdose have access to care is essential. The WHO stresses that such care must be of good quality, affordable, ethical, and evidence-based. The new guidelines are designed to support countries in addressing this disparity by providing clear, actionable recommendations.

Updated Treatment Recommendations

The WHO has published guidelines for the psychosocially assisted pharmacological treatment of opioid dependence, originally released in 2009, and community management of opioid overdose, released in 2014. The forthcoming updates build upon these existing frameworks to incorporate new evidence and address current challenges.

In the guidelines, the WHO recommends the use of a range of treatment options for opioid dependence. These include opioid agonist maintenance treatment, often referred to as OAMT. Medicines used in OAMT include methadone and buprenorphine.

Pharmacological treatment with opioid antagonists, such as naltrexone, is also included as an option. The guidelines emphasize the importance of psychosocial support in conjunction with pharmacological treatments. In the choice of treatment, the WHO recommends OAMT to be used for most patients.

WHO recommends OAMT to be used for most patients as the intervention with strongest evidence of effectiveness for variety of outcomes.

World Health Organization

Guideline Development Process

The updated recommendations were informed by a rigorous process in accordance with WHO methods for guideline development. This process considered the balance of benefits and harms, values and preferences, cost-effectiveness, equity, acceptability, and feasibility.

Comprehensive findings from systematic literature reviews of quantitative and qualitative evidence were examined by the Guideline Development Group (GDG). The GDG was responsible for updating the existing recommendations and formulating new ones based on the evidence reviewed.

This structured approach ensures that the recommendations are robust and applicable across different health systems. By focusing on evidence-based practices, the WHO aims to standardize care and improve outcomes for patients worldwide.

Goals for Community Management

A key component of the update involves the community management of opioid overdose. The guidelines aim to reduce deaths from opioid overdose through specific evidence-based recommendations. This includes strategies for prevention and immediate response within community settings.

Supporting countries in addressing the treatment gap is a primary objective. The guidelines are intended to help health systems expand access to effective care. By doing so, the WHO hopes to mitigate the morbidity and mortality associated with opioid dependence.

The announcement of these updates marks a continued effort by the World Health Organization to refine public health strategies regarding substance use. As the guidelines are finalized and disseminated, they will serve as a critical resource for healthcare providers and policymakers working to address the global opioid crisis.